Chemotherapy for Small Cell Lung Cancer: a Comprehensive Review

Overview

Journal Oncol Rev

Specialty Oncology

Date 2015 May 21

PMID 25992206

Citations 15

Authors

Syed Mustafa Karim

Jamal Zekri

Affiliations

Soon will be listed here.

Abstract

Combination chemotherapy is the current strategy of choice for treatment of small cell lung cancer (SCLC). Platinum containing combination regimens are superior to non-platinum regimens in limited stage-SCLC and possibly also in extensive stage-SCLC as first and second-line treatments. The addition of ifosfamide to platinum containing regimens may improve the outcome but at the price of increased toxicity. Suboptimal doses of chemotherapy result in inferior survival. Early intensified, accelerated and high-dose chemotherapy gave conflicting results and is not considered a standard option outside of clinical trials. A number of newer agents have provided promising results when used in combination regimens, for example, gemcitabine, irinotecan and topotecan. However, more studies are required to appropriately evaluate them. There is a definitive role for radiotherapy in LD-SCLC. However, timing and schedule are subject to further research. Novel approaches are currently being investigated in the hope of improving outcome.

Citing Articles

Advances in biomarkers for immunotherapy in small-cell lung cancer.

Li H, Zhao P, Tian L, Lu Y, Wang X, Shao W Front Immunol. 2024; 15:1490590.

PMID: 39723215 PMC: 11668642. DOI: 10.3389/fimmu.2024.1490590.

Extracellular vesicles from non-neuroendocrine SCLC cells promote adhesion and survival of neuroendocrine SCLC cells.

Jimenez L, Stolzenbach V, Ozawa P, Ramirez-Solano M, Liu Q, Sage J Proteomics. 2023; 24(11):e2300030.

PMID: 37926756 PMC: 11648350. DOI: 10.1002/pmic.202300030.

large-cell neuroendocrine carcinoma of the prostate: A case report and literature review.

Fukagawa E, Yuasa T, Inamura K, Hamada K, Fujiwara M, Komai Y IJU Case Rep. 2022; 5(6):505-510.

PMID: 36341182 PMC: 9626356. DOI: 10.1002/iju5.12527.

First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy.

Giunta E, Addeo A, Rizzo A, Banna G Front Med (Lausanne). 2022; 9:924853.

PMID: 35692538 PMC: 9174785. DOI: 10.3389/fmed.2022.924853.

Novel chalcone-derived pyrazoles as potential therapeutic agents for the treatment of non-small cell lung cancer.

Maciejewska N, Olszewski M, Jurasz J, Serocki M, Dzierzynska M, Cekala K Sci Rep. 2022; 12(1):3703.

PMID: 35260633 PMC: 8904451. DOI: 10.1038/s41598-022-07691-6.

References

Reck M, von Pawel J, Macha H, Kaukel E, Deppermann K, Bonnet R . Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst. 2003; 95(15):1118-27. DOI: 10.1093/jnci/djg017. View

Lee S, James L, Qian W, Spiro S, Eisen T, Gower N . Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax. 2008; 64(1):75-80. DOI: 10.1136/thx.2007.093872. View

Klasa R, Murray N, Coldman A . Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 1991; 9(3):499-508. DOI: 10.1200/JCO.1991.9.3.499. View

Ettinger D . The place of ifosfamide in chemotherapy of small cell lung cancer: the Eastern Cooperative Oncology Group experience and a selected literature update. Semin Oncol. 1995; 22(1 Suppl 2):23-7. View

Sculier J, Paesmans M, LECOMTE J, Van Cutsem O, Lafitte J, Berghmans T . A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer. 2001; 85(10):1444-51. PMC: 2363948. DOI: 10.1054/bjoc.2001.2114. View

Gregor A, Cull A, Stephens R, Kirkpatrick J, Yarnold J, Girling D . Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European.... Eur J Cancer. 1998; 33(11):1752-8. DOI: 10.1016/s0959-8049(97)00135-4. View

Nakanishi Y, Takayama K, Takano K, Inoue K, Osaki S, Wataya H . Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol. 1999; 22(4):399-402. DOI: 10.1097/00000421-199908000-00016. View

Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S . CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992; 10(8):1225-9. DOI: 10.1200/JCO.1992.10.8.1225. View

Jalal S, Bedano P, Einhorn L, Bhatia S, Ansari R, Bechar N . Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol. 2010; 5(12):2008-11. DOI: 10.1097/JTO.0b013e3181f77b6e. View

10.

Sundstrom S, Bremnes R, Kaasa S, Aasebo U, Hatlevoll R, Dahle R . Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002; 20(24):4665-72. DOI: 10.1200/JCO.2002.12.111. View

11.

Feld R, Evans W, Coy P, HODSON I, MacDonald A, Osoba D . Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol. 1987; 5(9):1401-9. DOI: 10.1200/JCO.1987.5.9.1401. View

12.

Higano C, Crowley J, Veith R, Livingston R . A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study. Invest New Drugs. 1997; 15(2):153-6. DOI: 10.1023/a:1005869008452. View

13.

Ichiki M, Rikimaru T, Gohara R, Koga T, Kawayama T, Matunami M . Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer. Oncology. 2003; 64(4):306-11. DOI: 10.1159/000070286. View

14.

Horn L, Dahlberg S, Sandler A, Dowlati A, Moore D, Murren J . Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009; 27(35):6006-11. PMC: 2793043. DOI: 10.1200/JCO.2009.23.7545. View

15.

Dy G, Miller A, Mandrekar S, Aubry M, Langdon Jr R, MORTON R . A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 2005; 16(11):1811-6. DOI: 10.1093/annonc/mdi365. View

16.

Inoue A, Ishimoto O, Fukumoto S, Usui K, Suzuki T, Yokouchi H . A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405. Ann Oncol. 2009; 21(4):800-803. DOI: 10.1093/annonc/mdp384. View

17.

Fried D, Morris D, Poole C, Rosenman J, Halle J, Detterbeck F . Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004; 22(23):4837-45. DOI: 10.1200/JCO.2004.01.178. View

18.

Lowenbraun S, Bartolucci A, Smalley R, Lynn M, Krauss S, DURANT J . The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer. 1979; 44(2):406-13. DOI: 10.1002/1097-0142(197908)44:2<406::aid-cncr2820440206>3.0.co;2-1. View

19.

Rizzo J, Elias A, Stiff P, Lazarus H, Zhang M, Oblon D . Autologous stem cell transplantation for small cell lung cancer. Biol Blood Marrow Transplant. 2002; 8(5):273-80. DOI: 10.1053/bbmt.2002.v8.pm12064365. View

20.

Shepherd F, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V . Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the.... J Clin Oncol. 2002; 20(22):4434-9. DOI: 10.1200/JCO.2002.02.108. View